Bobby Reddy
Principal investigator, leads Prenosis, Inc..
MedtechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$11.7MFederal grants as PI13 awards
1Patents grantedLatest Jun 8, 2021
71Papers1,979 citations
Federal awards and patents by year
AwardsPatents
13 awards · $11.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 21, 2026 | NIH | SBIR Phase II Derivation and Validation of the Heart Failure CardioScore: an AI Diagnostic for HeartFailure using Novel Biomarkers and Clinical Data | $1.2M | Prenosis, Inc. |
| Aug 21, 2025 | NIH | SBIR Phase II Clinical Validation of a Point-of-Care Precision Medicine Endotyping Platform | $700K | Prenosis, Inc. |
| Sep 24, 2024 | NIH | SBIR Phase II Clinical Validation of a Point-of-Care Precision Medicine Endotyping Platform | $700K | Prenosis, Inc. |
| Jun 25, 2024 | NIH | SBIR Phase II Use of Time Series Biomarker and Clinical Data to Construct a Time Trajectory Host Response Map | $1.3M | Prenosis, Inc. |
| Jun 21, 2024 | NIH | SBIR Phase II Combined Biomarker and EMR Data for Heterogeneous Treatment Effects and Surrogate Endpoints in Sepsis | $1.2M | Prenosis, Inc. |
| Jun 1, 2023 | NIH | SBIR Phase II Use of Time Series Biomarker and Clinical Data to Construct a Time Trajectory Host Response Map | $1.3M | Prenosis, Inc. |
| May 22, 2023 | NIH | SBIR Phase II Combined Biomarker and EMR Data for Heterogeneous Treatment Effects and Surrogate Endpoints in Sepsis | $1.2M | Prenosis, Inc. |
| May 19, 2023 | NIH | SBIR Phase II Use of Time Series Biomarker and Clinical Data to Construct a Time Trajectory Host Response Map | $1.3M | Prenosis, Inc. |
| Jul 30, 2021 | NIH | SBIR Phase II Collaborative Platform for Developing Sepsis Products by Leveraging Sepsis Endotypes Developed Using a Unified Biomarker-Clinical Dataset | $990K | Prenosis, Inc. |
| Sep 3, 2020 | NIH | SBIR Phase II Collaborative Platform for Developing Sepsis Products by Leveraging Sepsis Endotypes Developed Using a Unified Biomarker-Clinical Dataset | $990K | Prenosis, Inc. |
| Sep 18, 2018 | NSF | SBIR Phase II SBIR Phase II: Point of Care Device for High Frequency Stratification of Patient Populations at Risk of Sepsis | $705K | Prenosis, Inc. |
| Sep 7, 2017 | NIH | SBIR Phase I Point of Care Device for Reducing Overuse of Antibiotics in Potentially Septic Hospital Populations | $150K | Prenosis, Inc. |
| Jul 10, 2017 | NSF | SBIR Phase I SBIR Phase I: Point of Care Device for High Frequency Stratification of Patient Populations at Risk of Sepsis | $150K | Prenosis, Inc. |
2 patents as inventor
- US 11027274Prenosis, Inc.Jun 8, 2021
- US Prenosis, Inc.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#52
Awards as PI#77
Patents#284
Companies
- Prenosis, Inc.Leads (SEC Form D) · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.